Table 1.
CPP-conjugated therapeutics in clinical trial
| Disease | CPP-cargo | Number of enrolled patients | Status | ClinicalTrials.gov ID |
|---|---|---|---|---|
| Solid tumors | P28 | N = 15 | Phase I completed 2014 | NCT00914914 |
| CNS malignancies | P28 | N = 18 | Phase I completed 2017 | NCT01975116 |
| Postherpetic neuralgia | TAT-ɛPKC inhibitor | N = 23 | Phase II completed 2011 | NCT01106716 |
| Acute inner ear hearing loss | TAT-AM 111 | N = 256 | Phase III completed 2017 | NCT02561091 |
| Tumor imaging | ACPPs-Cy5 and Cy7 | N = 27 | Phase I completed 2017 | NCT02391194 |
| Cervical dystonia | TAT-Daxibotulinumtoxin A | N = 37 | Phase II completed 2019 | NCT02706795 |
| Postoperative ocular inflammation | TAT-XG102 | N = 339 | Phase III completed 2017 | NCT02235272 |